Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Neoplasm Metastasis
Interventions: DRUG: everolimus (RAD001)
Sponsor: Novartis Pharmaceuticals